8月27日，亚盛医药盘中上涨13.18%，报37.26港元，成交额1.66亿港元。
消息面上，公司于8月20日公布中期业绩，上半年实现总收入3.02亿元人民币，同比增长29%；产品销售收入2.82亿元，同比增长33%，耐立克与利生妥双引擎驱动商业化持续放量。此外，国泰海通证券首予公司"增持"评级，目标价59.09港元，预计全年营收10.15亿元，同比增长约77%。公司近期还聘任CBO及CCO两位高管，加速海外商业化布局，全球注册III期临床同步推进，基本面催化集中释放。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.